eligibility_summary
Adults (>=18) with pathologic epithelial ovarian, fallopian tube, or primary peritoneal cancer, tumor available for HER2 IHC (1+/2+/3+), ECOG 0-1, life expectancy >12 weeks, adequate organ function, measurable disease, WOCBP: negative pregnancy test and effective contraception/sterile/menopausal. Exclude prior HER2 ADC or similar TKI, platinum-refractory, untreated CNS mets, obstruction, recent major bleeding or thrombosis, serious CV disease, unresolved >=G2 AEs, recent major surgery, other recent cancers, vessel invasion, symptomatic effusions, allergy, pregnancy, or serious comorbidities.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Disitamab vedotin (RC48), a HER2‑targeted antibody–drug conjugate (IgG1 anti‑HER2 linked to MMAE, a microtubule inhibitor) that binds HER2 on tumor cells, is internalized, releases MMAE to cause mitotic arrest/apoptosis and may trigger ADCC, plus anlotinib (AL3818), an oral multi‑target tyrosine‑kinase inhibitor of VEGFR2/3, FGFR1‑4, PDGFRα/β, c‑KIT, and RET that suppresses angiogenesis and tumor growth. Targets/pathways: HER2/ERBB2 on ovarian cancer cells, VEGF/VEGFR signaling in tumor endothelial cells, with additional blockade of FGFR/PDGFR/c‑KIT pathways in the tumor microvasculature/stroma. Aim: evaluate synergistic efficacy in HER2‑expressing, platinum‑resistant recurrent ovarian/fallopian tube/primary peritoneal cancer (primary endpoint: ORR).